方盛制药：控股子公司1.1类中药创新药紫英颗粒获得药物临床试验批准通知书

Core Viewpoint - The announcement highlights that Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [1] Company Summary - Fangsheng Pharmaceutical's Ziying Granules is classified as a Class 1 innovative traditional Chinese medicine [1] - The product is specifically designed for the treatment of chronic pelvic pain associated with pelvic inflammatory disease, characterized by damp-heat and blood stasis syndrome [1] - As of the date of the announcement, Ziying Granules have not yet been launched in domestic or international markets [1]